A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. - Wikidata - awgldk - TriplyDB

A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal.

A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal.

http://www.wikidata.org/entity/Q46550903

about

Acellular vaccines for preventing whooping cough in children Acellular vaccines for preventing whooping cough in children Acellular vaccines for preventing whooping cough in children Acellular vaccines for preventing whooping cough in children Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies.Concerns about immunisation Pertussis vaccine trials in the 1990s Profile: the Niakhar Health and Demographic Surveillance System Pertussis: Microbiology, Disease, Treatment, and Prevention.Tetanus-diphtheria-acellular pertussis vaccination of adults in the USA.Acellular pertussis vaccine efficacy: An updated systematic review and meta -analysis.A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis.Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis.Analysis of Bordetella pertussis populations in European countries with different vaccination policies Protective effects of pertussis immunoglobulin (P-IGIV) in the aerosol challenge model Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years Evaluation of an immunoglobulin G enzyme-linked immunosorbent assay for pertussis toxin and filamentous hemagglutinin in diagnosis of pertussis in Senegal Acellular pertussis vaccines and the role of pertactin and fimbriae.A regulatory role for interleukin 4 in differential inflammatory responses in the lung following infection of mice primed with Th1- or Th2-inducing pertussis vaccines.Update on pertussis in children.Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis.Quantitative priming with inactivated pertussis toxoid vaccine in the aerosol challenge model.Non-specific effects of vaccination on child survival? A prospective study in Senegal.Seroprevalence of pertussis in Senegal: a prospective study Pertussis re-emergence in the post-vaccination era Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine.Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children.Pertussis: persistent pathogen, imperfect vaccines.Effect of different forms of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine in a murine model.Seroprevalence of pertussis in the Gambia: evidence for continued circulation of bordetella pertussis despite high vaccination rates.Short-lived immunity against pertussis, age-specific routes of transmission, and the utility of a teenage booster vaccine.Toxicity and potency evaluation of pertussis vaccines.Acellular pertussis vaccines for use among infants and young children.Bordetella pertussis transmission.Airborne transmission of Bordetella pertussis.Assessment of antibody level and avidity against Bordetella pertussis in a cohort of Egyptian individuals aged 1-18 years.Comparison of Three Whole-Cell Pertussis Vaccines in the Baboon Model of Pertussis Protective Effect of Contemporary Pertussis Vaccines: A Systematic Review and Meta-analysis.Delayed adaptive immunity is related to higher MMR vaccine-induced antibody titers in children Immunogenicity and safety of a DTaP-IPV//PRP approximately T combination vaccine given with hepatitis B vaccine: a randomized open-label trial.

P2860

Q24193554-3747A4FF-C911-4417-A838-9B1B88F42837 Q24201103-023CD0F7-F8C2-42CC-B940-AEB13895D637 Q24234899-5B870D53-8584-439E-A0BC-9BEDB6B69C6E Q24243261-76E93A19-D6C0-48E6-8943-4826F79449E4 Q24522458-2516613B-397A-4D70-9BDA-2C7E3D0F5E24 Q24524552-F16F7DBF-9CDC-471D-BBBF-7505F6DC07BB Q27025393-4D070B07-425A-4879-9E96-5176F75BD857 Q28679578-1BAC9F11-5FFB-4BE9-86B3-B8217F9A1E6D Q30251684-F30E8656-166F-4599-800F-BF5666F70D6B Q33156368-7B6FC17A-591F-4EDF-9EFE-589129A6651F Q33642326-4679FCD7-2DF2-4147-B8AB-289CDBD44561 Q33750257-4E3DA4B5-45EF-4CA2-91C6-B2558ED1E2D6 Q33825642-CE6D0540-B39F-4974-B01F-3E35F2BB4F2B Q33856228-4C40380B-3B22-4DE1-A81B-D9076A8A5B86 Q33866775-51A1C1A9-1801-400F-8F6D-1CB3511B6950 Q33974293-861884DD-9EFF-4886-80DB-C9BB0F665C88 Q33991178-5C96F525-4CC5-422E-9B06-9765CC356DE2 Q34002283-363E1D0B-B14E-4C12-B85F-5F72D3B88507 Q34003563-B9E74240-035B-48D6-B265-E994FF3ED24A Q34095301-4E90A25F-4E7E-43DD-B1C9-5AEF07E60E16 Q34126969-0FD60FCA-E908-4EBF-AEEF-3E5D4A28C756 Q34129001-5B0625ED-0B04-47B3-BC28-410560AE10E2 Q34453927-4F070440-7B8D-4432-9B58-5AB726D5CDE8 Q34465419-6A8C2420-3005-42D1-A3EB-7A5F4E28CB4C Q34636630-088EADD6-7771-4781-8A8A-A2D053FDDA04 Q34671882-9D5A9D9F-2189-443A-AD4E-E4DCBCE6549B Q35113522-BB03D0AE-C953-4869-8719-98ECA35C5811 Q35193561-5B34F2C8-A723-404C-B0F1-E1773DCD6DFB Q35220336-CD9A9AE8-B357-4701-ACBD-B9C15FF7B030 Q35566869-F7EFDCF7-7FAC-401A-9EE2-74D79591074F Q35634111-D088D47B-A968-4127-B9EC-0B4282941BCC Q35648263-AB49FED7-A1E1-47FE-9D13-F0C09A86EFE1 Q35753402-1EC50802-08FB-41F8-A36F-8DBF97008273 Q36226634-233EFE99-5758-4523-B205-761F009C9ABF Q36408279-2A298B43-3203-401C-8470-3A7C7D4B9068 Q36436918-DA9CDA26-EDBF-4970-9401-3BE1B4A0CC80 Q36457650-581653DC-8EA7-4A9A-BD3C-AB7997149831 Q36783198-7A667A25-4E82-4D2C-A6F8-3523F564C43E Q36865091-13D5202F-824A-4DA8-9403-7E565FB178E8 Q37108887-C6D0A9ED-242C-4E54-B722-F885FB798AC3

P2860

A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal.

http://www.wikidata.org/entity/Q46550903

description

1997 nî lūn-bûn

@nan

1997年の論文

@ja

1997年学术文章

@wuu

1997年学术文章

@zh

1997年学术文章

@zh-cn

1997年学术文章

@zh-hans

1997年学术文章

@zh-my

1997年学术文章

@zh-sg

1997年學術文章

@yue

1997年學術文章

@zh-hant

name

A randomized double-blind tria ...... pertussis vaccine in Senegal.

@en

A randomized double-blind tria ...... pertussis vaccine in Senegal.

@nl

type

label

A randomized double-blind tria ...... pertussis vaccine in Senegal.

@en

A randomized double-blind tria ...... pertussis vaccine in Senegal.

@nl

prefLabel

A randomized double-blind tria ...... pertussis vaccine in Senegal.

@en

A randomized double-blind tria ...... pertussis vaccine in Senegal.

@nl

P1433

Q46550903-52F48BD9-A980-445D-894C-C489B590D8C5

P1476

Q46550903-F2923105-2686-4BB1-9117-E15451B1C1E7

P2093

Q46550903-1C8E007B-855A-4E34-AAC7-D903A6FE0311

Q46550903-36BF2FB5-22C2-490E-A3D7-CF5EE14DC06C

Q46550903-6A4DF027-7D4D-4E7C-BCED-D327ACE436F8

Q46550903-70CEEA73-42E4-446B-AC3B-80AFF1C1A14B

Q46550903-7F8C3277-9B2A-432C-B146-3857FA19BBCB

Q46550903-86CB4C59-04AF-434E-BC3E-5ACECCCF82AF

Q46550903-ADA27F56-DF83-4E02-A8D5-1078BBAF4767

Q46550903-B03727B0-0803-47FE-A0C7-99A4B3EFB085

Q46550903-CF088424-DA9A-440F-96E0-15ECB7795E48

Q46550903-D18F15FC-F963-4E85-8AC1-E384E156F3CD

P304

Q46550903-320E8545-269D-4D7B-A47F-1F2DD7B54B89

P31

Q46550903-AC94AC93-4DC9-447A-A8AE-7B7B09D2921E

P356

Q46550903-21665701-7F4A-49B4-89AA-FC5EAD149939

P407

Q46550903-460B8AB7-F216-4700-B6E9-CDE1F05D255F

P433

Q46550903-6903AFBC-C33D-4932-92EA-E1B8B8D09093

P478

Q46550903-0A1E2C67-2F6F-41C9-8FEC-C9BD93F9B2CC

P577

Q46550903-EDBFF1E0-AF93-4CD2-B853-EA1678FE0EBC

P698

Q46550903-BEB16681-1032-489D-9958-91948FC6A26D

P356

S0264-410X(97)00100-X

P1433

P1476

A randomized double-blind tria ...... pertussis vaccine in Senegal.

@en

P2093

Cadoz M

http://www.w3.org/2001/XMLSchema#string

Chabirand L

http://www.w3.org/2001/XMLSchema#string

Guiso N

http://www.w3.org/2001/XMLSchema#string

Hoffenbach A

http://www.w3.org/2001/XMLSchema#string

Iteman I

http://www.w3.org/2001/XMLSchema#string

Kane CT

http://www.w3.org/2001/XMLSchema#string

Knudsen K

http://www.w3.org/2001/XMLSchema#string

Mboup S

http://www.w3.org/2001/XMLSchema#string

Preziosi MP

http://www.w3.org/2001/XMLSchema#string

Sanden G

http://www.w3.org/2001/XMLSchema#string

P304

1606-1612

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0264-410X(97)00100-X

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

1997-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9364690

http://www.w3.org/2001/XMLSchema#string